A novel cell-penetrating peptide supports hair follicle growth through anti-inflammatory and growth factor–associated mechanisms in preclinical models
Abstract
Hair loss remains a prevalent condition for both men and women worldwide. Current therapies for this condition, including minoxidil and finasteride, are limited by inconsistent efficacy, side effects, and dependence on continuous use. Cell-penetrating peptides (CPPs) have emerged as promising bioactive agents in dermatology due to their ability to traverse cell membranes and modulate multiple biological pathways relevant to hair regeneration. This study aimed to identify and evaluate a novel synthetic CPP, DualPep-ALO, for its potential to promote hair growth by restoring the follicular microenvironment and stimulating key regenerative pathways. Using the intra-dermal delivery technology platform (REMEDI), over 200 human protein–derived peptides were screened for cell-penetrating potential. The lead candidate, DualPep-ALO, was selected based on its proliferative effect on human follicle dermal papilla cells and upregulation of Wnt/β-catenin and ERK signaling. In vitro and ex vivo assays were conducted to assess antioxidant enzyme activity, inflammatory cytokine suppression, follicle elongation, anagen maintenance, and growth factor expression. DualPep-ALO significantly enhanced human follicle dermal papilla cell proliferation, restored antioxidant enzyme (SOD, CAT) activity, and suppressed pro-inflammatory cytokines (TNF-α, IL-1β, IL-6, PGE-2). In ex vivo human scalp tissue, it promoted hair follicle elongation, maintained the anagen phase, and upregulated VEGF, HGF, and EGF…
Read the paper
Related studies
- Antioxidant efficacy and the upregulation of Nrf2-mediated HO-1 expression by (+)-lariciresinol, a lignan isolated from Rubia philippinensis, through the activation of p38
- Anti-influenza virus activity of green tea by-products in vitro and efficacy against influenza virus infection in chickens
- Therapeutic Potential of Mesenchymal Stem Cells (MSCs) and MSC-Derived Extracellular Vesicles for the Treatment of Spinal Cord Injury
- The intratumoral administration of ferucarbotran conjugated with doxorubicin improved therapeutic effect by magnetic hyperthermia combined with pharmacotherapy in a hepatocellular carcinoma model
- Enhanced anticancer efficacy of TRAIL-conjugated and odanacatib-loaded PLGA nanoparticles in TRAIL resistant cancer
- In vivo tracking of bioorthogonally labeled T-cells for predicting therapeutic efficacy of adoptive T-cell therapy
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.